Journal article
Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder
Molecular neuropsychiatry, Vol.3(4), pp.197-213
05/2018
DOI: 10.1159/000485800
PMCID: PMC5981774
PMID: 29888231
Abstract
This study developed potential blood-based biomarker tests for diagnosing and differentiating schizophrenia (SZ), bipolar disorder type I (BD), and normal control (NC) subjects using mRNA gene expression signatures. A total of 90 subjects (
n
= 30 each for the three groups of subjects) provided blood samples at two visits. The Affymetrix exon microarray was used to profile the expression of over 1.4 million probesets. We selected potential biomarker panels using the temporal stability of the probesets and also back-tested them at two different visits for each subject. The 18-gene biomarker panels, using logistic regression modeling, correctly differentiated the three groups of subjects with high accuracy across the two different clinical visits (83–88% accuracy). The results are also consistent with the actual data and the “leave-one-out” analyses, indicating that the models should be predictive when applied to independent data cohorts. Many of the SZ and BD subjects were taking antipsychotic and mood stabilizer medications at the time of blood draw, raising the possibility that these drugs could have affected some of the differential transcription signatures. Using an independent Illumina data set of gene expression data from antipsychotic medication-free SZ subjects, the 18-gene biomarker panels produced a receiver operating characteristic curve accuracy greater than 0.866 in patients that were less than 30 years of age and medication free. We confirmed select transcripts by quantitative PCR and the nCounter® System. The episodic nature of psychiatric disorders might lead to highly variable results depending on when blood is collected in relation to the severity of the disease/symptoms. We have found stable trait gene panel markers for lifelong psychiatric disorders that may have diagnostic utility in younger undiagnosed subjects where there is a critical unmet need. The study requires replication in subjects for ultimate proof of the utility of the differential diagnosis.
Details
- Title: Subtitle
- Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder
- Creators
- Marquis Philip Vawter - Functional Genomics Laboratory, Department of Psychiatry, University of California, Irvine, California, USARobert Philibert - Department of Psychiatry, University of Iowa, Iowa City, Iowa, USABrandi Rollins - Functional Genomics Laboratory, Department of Psychiatry, University of California, Irvine, California, USAPatricia L Ruppel - Innovative Analytics, Inc., Kalamazoo, Michigan, USATerry W Osborn - Laguna Diagnostics, LLC, The Villages, Florida, USA
- Resource Type
- Journal article
- Publication Details
- Molecular neuropsychiatry, Vol.3(4), pp.197-213
- Publisher
- S. Karger AG
- DOI
- 10.1159/000485800
- PMID
- 29888231
- PMCID
- PMC5981774
- ISSN
- 2296-9209
- eISSN
- 2296-9179
- Language
- English
- Date published
- 05/2018
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984071799302771
Metrics
21 Record Views